Hikal Ltd.

Market Capital
₹3,829 Cr.
P/E
48.61
Share Price
₹ 319.45 9.05 (2.92%)

Hikal Ltd.

Quick View
₹ 319.45 9.05 (2.92%)
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Forensics
ROE
Net Profit Margin is responsible for ROE increase over last 10 years
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
ROCE of the company has decreased even without significant capex
Pledge
Promoters have not pledged a significant portion of their holding
Debt
Company should not have issues servicing its debt
Current vs Historic Valuation
Company is trading at a premium to 3yr historic valuations
Working Capital
Working Capital of the company seems to be under control
Revenue Recognition
Company is converting accounting profit to cash
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Share price
Share price has increased over last 10 years due to earnings
Contingent Liabilities
Company does not have significant contingent liabilities
Promoter Holding
Promoter has not sold any shares in the last 90 days
Retail Holding
Retail has been selling the stock which is usually a good time to buy
ROE
Latest
15.03%
3yr Average
13.21%
5yr Average
12.96%
Net Profit Margin
Latest
8.26%
3yr Average
7.2%
5yr Average
6.81%
ROCE
Latest
16.65%
3yr Average
17.0%
5yr Average
17.19%
Debt to Equity
Latest
0.63
3yr Average
0.69
5yr Average
0.78
Market Share
40% (as of Mar 19)
Gabapentin - Market Share
locked Source
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Product Wise Break-Up -Crop Protection

locked
Source
|
Latest
|
locked
Historic

Product Wise Break-Up -Pharmaceuticals

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • Management Compensation as a % of Sales (%)
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Hikal Ltd.
    View the discussion on ValuePickr
    What Makes Hikal Special - Value Educator
    Pharmaceutical Sector
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    Nutraceuticals- Industry Overview - Value Educator
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Pharma Compliance In-Depth - Amit Rajan
    Deep Dive into Pharma Sector - Omkara Capital
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    How The Pharma Industry Works - PPFAS
    timeline
    Sign Up for Free